A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma
This phase 1 study (clinical trial NCT00477815) was conducted to determine the maximum tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan (90Y-Zevalin) with high dose melphalan (HDM) therapy in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT).
 13:07 - 20/09/2017 - Comments : 0More >>
In vitro and in vivo imaging and tracking of intestinal organoids from human-induced pluripotent stem cells
Human intestinal organoids (hIOs) derived from human pluripotent stem cells (hPSCs) have immense potential as a source of intestines.
 08:24 - 20/09/2017 - Comments : 0More >>
Global CAR T Cell Therapy Market to Reach US$ 8.5 Billion by 2028
The Global Car T Cell Therapy Market is expected to be valued at US$ 8.5 Billion by 2028, as analyzed by Coherent Market Insights. Increasing demand for genetically engineered treatment approach for high success rate in cancer treatment along with growing cancer incidence rate are key factors driving demand for CAR T cell therapy products worldwide.
 14:03 - 19/09/2017 - Comments : 0More >>
Engineered T cells for all
Gene-engineered autologous T cells with chimeric antigen receptors (CARs) against CD19 (CART19 cells) have been effective against patients with CD19+ B cell malignancies.
 09:46 - 19/09/2017 - Comments : 0More >>
UCLA Launches First-of-Its-Kind Stem Cell Trial to Combat Cancer
Scientists at UCLA have launched the first genetically engineered blood stem cell clinical trial to fight cancer thanks to $20 million in voter-approved funds earmarked for stem cell research, university officials announced Monday.
 11:55 - 18/09/2017 - Comments : 0More >>
Gene therapy restores auditory and vestibular function in a mouse mode
Because there are currently no biological treatments for hearing loss, we sought to advance gene therapy approaches to treat genetic deafness.
 11:30 - 18/09/2017 - Comments : 0More >>
6 Companies Developing Cell Therapy Treatments for Diabetes6 Companies Developing Cell Therapy Treatments for Diabetes
With an aging population, obesity on the rise, and sedentary lifestyles becoming increasingly common, diabetes has grown into a major health concern in the U.S. and worldwide. According to the Center for Disease Control (CDC), 29.1 million people or 9.3% of the U.S. population has diabetes, including an estimated 8.1 million who are undiagnosed. According to the American Diabetes Association, the 2012 cost of this disease in the U.S. was “$245 billion per annum or approximately $500,000 every minute.”
 11:07 - 17/09/2017 - Comments : 0More >>
A “Fourth-Generation” DNA Base Editor Could Replace CRISPR
The latest news in genetic science has been dominated by the CRISPR/Cas9 technique over the past five years. But a new “fourth-generation” DNA base editor could see CRISPR dethroned, according to a recent study published in Science Advances.
 08:09 - 17/09/2017 - Comments : 0More >>
CD19-Specific CAR T-Cell Therapy Effective in Ibrutinib-Refractory CLL
Anti-CD19 chimeric antigen receptor (CAR)-modified T-cell therapy was highly effective in patients with high-risk chronic lymphocytic leukemia (CLL) who had previously failed treatment with ibrutinib, according to the results of a study published in the Journal of Clinical Oncology.
 12:44 - 16/09/2017 - Comments : 0More >>
Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse
Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its proprietary ACTolog® approach. The IMA101 phase I trial is the first industry-sponsored trial using products consisting of autologous cytotoxic T lymphocytes targeting defined tumor antigens using Immatics’ novel and proprietary target warehouse. This single-center study is now open for enrollment at The University of Texas MD Anderson Cancer Center in Houston, Texas.
 20:14 - 13/09/2017 - Comments : 0More >>
Genome editing for scalable production of alloantigen‐free lentiviral vectors for in vivo gene therapy
New electric mesh device gives the heart an electromechanical hug
Phase 1 clinical trial using mbIL21 ex-vivo expanded donor-derived NK cells after haploidentical transplantation
Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1-2 Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A
Engraftment and in vivo proliferation advantage of gene corrected mobilized CD34+ cells from Fanconi anemia patients
Pregnant womens stem cells could treat osteoporosis, say scientists
Cambridge scientists create first self-developing embryo from stem cells
Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus
FDA Commissioner Announces Stem Cell Enforcement Shift, Plans to Develop Comprehensive Regenerative Medicine Policies
PUMA gene delivery to synoviocytes reduces inflammation and degeneration of arthritic joints